Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward

In 2017, there is no adjuvant systemic therapy proven to increase overall survival in non-metastatic renal cell carcinoma (RCC). The anti-PD-1 antibody nivolumab improves overall survival in metastatic treatment refractory RCC and is generally tolerable. Mouse solid tumor models have revealed a bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Harshman, L.C., Drake, C.G., Haas, N.B., Manola, J., Puligandla, M., Signoretti, S., Cella, D., Gupta, R.T., Bhatt, R., Van Allen, E., Lara, P., Choueiri, T.K., Kapoor, A., Heng, D.Y.C., Shuch, B., Jewett, M., George, D., Michaelson, D., Carducci, M.A., McDermott, D., Allaf, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179104/
https://www.ncbi.nlm.nih.gov/pubmed/30334002
http://dx.doi.org/10.3233/KCA-170010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179104/
https://www.ncbi.nlm.nih.gov/pubmed/30334002
http://dx.doi.org/10.3233/KCA-170010

Ejemplares similares